0.00Open0.00Pre Close0 Volume0 Open Interest10.00Strike Price0.00Turnover204.95%IV49.93%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier13DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.2029Delta0.1079Gamma26.68Leverage Ratio-0.0278Theta0.0004Rho5.41Eff Leverage0.0036Vega
Amneal Pharmaceuticals Stock Discussion
Benzinga· 2 mins ago
Novel 505(b)(2) presentation of a key injectable for treating non-squamous non-small cell lung cancer and malignant pleural mesothelioma, does not require reconstitution, dilution, or refrigeration
Amneal plans to launch two to three branded oncology 505(b)(2) products per year going forward – this is the first of 2024
Wait for institutions to offer guidance before taking out gains !
DONT PaNICK
short sellers need to exit their position to cover, HOLD the GAIN(S)
Amneal's medicine is an oral formulation of the carbidopa-levodopa combo used to treat Parkinson's disease. IPX203 is currently under review in the US.
Zambon will seek regulatory approval and commercialize IPX203 in Europe, Amneal said.
Financia...
The original NDA for IPX203 resulted in a Complete Response Let...
No comment yet